Bio-Techne Corp
NASDAQ:TECH

  • LAST PRICE
    367.1000
  • TODAY'S CHANGE (%)
    -10.1200 (-2.6828%)
  • Bid / Lots
    0.0000/ 0
  • Ask / Lots
    418.0200/ 1
  • Open / Previous Close
    377.3300 / 377.2200
  • Day Range
    366.5550
    379.6800
  • 52 Week Range
    311.0300
    543.8500
  • Volume
    399,498

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Recent News

Jan 18, 2022

9:21AM ET on Tuesday Jan 18, 2022 by Thomson Reuters

7:00AM ET on Tuesday Jan 18, 2022 by PR Newswire

Jan 17, 2022

8:00AM ET on Monday Jan 17, 2022 by PR Newswire

Jan 13, 2022

9:26AM ET on Thursday Jan 13, 2022 by MT Newswires

Jan 7, 2022

4:01PM ET on Friday Jan 07, 2022 by PR Newswire
0 New Today

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
TECH
Bio-Techne Corp
14.4B
84.8x
+4.37%
ALNY
Alnylam Pharmaceuticals Inc
16.3B
-19.1x
---
EXAS
Exact Sciences Corp
12.9B
-14.9x
---
ARGX
argenx SE
14.3B
-39.9x
---
BMRN
Biomarin Pharmaceutical Inc
15.5B
-335.1x
---
QGEN
Qiagen NV
11.2B
19.0x
+22.05%
As of 2022-01-22

Company Information

Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Contact Information

Headquarters
614 McKinley Pl NEMINNEAPOLIS, MN, United States 55413-2610
Phone
612-379-8854
Fax
612-656-4400

Executives

Independent Chairman of the Board
Robert Baumgartner
President, Chief Executive Officer, Director
Charles Kummeth
Chief Financial Officer, Executive Vice President - Finance
James Hippel
President - Protein Sciences
N. David Eansor
President - Protein Sciences Segment
William Geist

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$14.4B
Revenue (TTM)
$984.6M
Shares Outstanding
39.3M
Dividend Yield
0.35%
Annual Dividend Rate
1.2800 USD
Ex-Dividend Date
11-10-21
Pay Date
11-26-21
Beta
1.30
EPS
$4.33
Book Value
$40.12
P/E Ratio
84.8x
Price/Sales (TTM)
14.7
Price/Cash Flow (TTM)
54.1x
Operating Margin
25.54%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.